Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Reexamination Certificate
2006-03-28
2006-03-28
Harris, Alana M. (Department: 1643)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
C424S130100, C424S133100, C424S277100, C424S093700, C424S009710, C530S387300
Reexamination Certificate
active
07018632
ABSTRACT:
According to the invention there is described a method for ex vivo immunization of humans and animals comprising the following steps:a) isolating autologous tumor cells;b) treating the tumor cells to prevent the survival thereof following reinfusion;c) incubating the thus treated tumor cells with intact heterologous bispecific and/or trispecific antibodies showing the following properties:α—binding to a T cell;β—binding to at least one antigen on a tumor cell;γ—binding, by their Fc portion (in the case of bispecific antibodies), or by a third specificity (in the case of trispecific antibodies) to Fc receptor-positive cells.
REFERENCES:
patent: 4844893 (1989-07-01), Honsik et al.
patent: 5484596 (1996-01-01), Hanna et al.
patent: 5837243 (1998-11-01), Deo et al.
patent: 5911987 (1999-06-01), Volker et al.
patent: 5985276 (1999-11-01), Lindhofer et al.
patent: 0 826 695 (1998-03-01), None
Lindhofer, H. et al. Preferential species-restricted heavy/ligh chain pairing in rat/mouse quadromas. J. Immunology, 155: 219-225, 1995.
Renner, C., et al, Science 264:833-835, 1994.
H.G. Gottlinger et al.Int. J. Cancer(1986) 38: 47-53.
G.C. deGast et al.Cancer Immunol Immunother(1995) 40:390-396.
B.J. Kroesen et al.Br. J. Cancer(1994) 70: 652-661.
J-H. Qian et al.The Journal of Immunology(May 1, 1991) 146: 3250-3256.
R. Renner et al.Cancer Immunol Immunother(1997) 44: 70-76.
L.M. Weiner et al.Cancer Research(Oct. 15, 1995) 55: 4586-4592.
Lindhofer et al., “Bispecific antibodies target operationally tumor-specific antigens in two leukemia relapse models,”Blood(1996) 88(12): 4651.
Lindhofer et al., “Increased tumor-specificity and -elimination by selectively binding bispecific antibodies in vivo,” Abstract 348. ISSN: 0301-472X, XP002084410.
Lindhofer et al., “Bispecific antibodies effectively purge cancer cells from peripheral blood stem cell collections without affecting colony forming units,” Abstract 527, ISSN: 0301-472X, XP002048523.
Wollenberg et al., “A bispecific antibody induces efficient killing of tumor cells: Phase I-trail in patients with HNSCC,” Abstract 15.16. ISSN: 00007-0920, XP002084411.
Bornkamm Georg
Kolb Hans-Joachim
Lindhofer Horst
Zeidler Reinhard
GSF-Forschungszentrum für Umwelt und Gesundheit GmbH
Harris Alana M.
Holleran Anne L.
Townsend and Townsend / and Crew LLP
LandOfFree
Method for ex vivo immunization using heterologous intact... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for ex vivo immunization using heterologous intact..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for ex vivo immunization using heterologous intact... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3609622